XML 76 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Note 7 - Shareholders' Equity
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Shareholders' Equity and Share-based Payments [Text Block]
Note
7
- Shareholders' Equity
 
a.
Stock-Based Compensation Expense
 
We recorded non-cash stock compensation expense in each period as follows:
 
   
Year ended December 31
 
   
201
9
   
201
8
 
Stock options
  $
623
    $
817
 
Restricted stock grants
   
130
     
73
 
Total
  $
753
    $
890
 
 
These are more fully discussed as follows:
 
b.
Stock Options
 
We have various stock-based employee compensation plans, for which compensation cost is recognized in the financial statements. The cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity award).
 
Our shareholders have approved various equity-based plans that permit the grant of stock options, restricted stock and other equity-based awards. In addition, our shareholders have approved the grant of stock options outside of these plans.
 
In
June 2004,
our shareholders adopted the
2004
Long-Term Incentive Plan (
“2004
LTIP”) pursuant to which we were authorized to issue up to
750,000
shares of common stock and grant stock options, restricted stock awards, stock appreciation rights and other stock-based awards. Through shareholder approved amendments to the LTIP in
2006,
2008,
2011,
and
2013,
the total number of shares authorized under the
2004
LTIP was increased to
2,900,000.
 
In
June 2014,
our shareholders approved the
2014
Long-Term Incentive Plan (
“2014
LTIP”) as the successor plan to the
2004
LTIP that expired on
June 10, 2014.
Under the
2014
LTIP, a total of
1,750,000
shares of common stock will be available for grant of awards. Of the total number of shares of common stock available for awards under the
2014
LTIP,
no
more than
800,000
shares of common stock
may
be used for awards other than stock options and stock appreciation rights.  Grants under the
2014
LTIP
may
be awarded through
June 2, 2024.
 
Stock options granted under the LTIPs are either Incentive Stock Options (“ISOs”) or Non-Qualified Stock Options (“NQSOs”).  Key employees are eligible to receive ISOs and NQSOs; however, directors and consultants are eligible to receive only NQSOs. Most ISOs vest over a
three
-year period and expire on the
seventh
anniversary of the grant date.  As of
December 31, 2019,
there were
610,628
stock options outstanding under the
2004
LTIP and
931,164
stock options outstanding under the
2014
LTIP.
 
On
December 30, 2010,
pursuant to the terms of his employment agreement, we granted our President and Chief Executive Officer, Michael D. Popielec, options to purchase shares of common stock under the
2004
LTIP as follows: (i)
50,000
shares at
$6.42,
vesting in annual increments of
12,500
shares over a
four
-year period commencing
December 30, 2011; (
ii)
250,000
shares at
$6.42,
vesting in annual increments of
62,500
shares over a
four
-year period commencing
December 30, 2011; (
iii)
200,000
shares at
$10.00,
with vesting to begin on the date the stock reaches a closing price of
$10.00
per share for
15
trading days within a
30
-day trading period, with such vesting in annual increments of
50,000
shares over the
four
anniversary dates of that date; and (iv)
200,000
shares at
$15.00,
with vesting to begin on the date the stock reaches a closing price of
$15.00
per share for
15
trading days within a
30
-day trading period, with such vesting in annual increments of
50,000
shares over the
four
anniversary dates of that date. The options set forth in items (ii), (iii) and (iv) were subject to shareholder approval of an amendment to the
2004
LTIP, which approval was obtained on
June 7, 2011.
 
All such options in items (i) and (ii) were due to expire on
December 30, 2017.
On
April 19, 2017,
the Company’s Board of Directors extended the expiration date to
December 30, 2020.
 
All such options in items (iii) and (iv) were due to expire as of the later of
December 30, 2017
and
five
years after the initial vesting commences, but in
no
event later than
December 30, 2020.
On
July 25, 2018,
the Company’s Board of Directors modified the option in item (iii) such that the option will vest immediately upon the Company’s common stock
first
reaching a closing price
$10.00
for
15
trading days in a
30
trading-day period. The option became fully vested during the
third
quarter of
2018
and expires
December 30, 2020.
The transaction has been accounted for as an equity award modification pursuant to Accounting Standards Codification Topic
718,
Compensation – Stock Compensation. During the
third
quarter
2018,
the Company recognized compensation cost of
$182
representing the incremental fair value of the modified award computed as of the modification date as the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The incremental fair value was determined using a Monte Carlo simulation option-pricing model consistent with the valuation methodology used to value and recognize the original award. The market-based conditions for the option in item (iv) had
not
been met as of
December 31, 2019.
 
As of
December 31, 2019,
there was
$737
of total unrecognized compensation costs related to outstanding stock options, which we expect to recognize over a weighted average period of
1.2
years.
 
We use the Black-Scholes option-pricing model to estimate fair value of stock-based awards. The following weighted average assumptions were used to value options granted during the years ended
December 31, 2019
and
2018:
 
   
Year ended December 31
 
   
2019
   
2018
 
Risk-free interest rate
   
1.8
%    
2.6
%
Volatility factor
   
48.3
%    
46.8
%
Weighted average expected life (years)
   
5.3
     
5.0
 
Forfeiture rate
   
10.0
%    
10.0
%
Dividends
   
0.0
%    
0.0
%
 
We used a Monte Carlo simulation option-pricing model to estimate the fair value of market performance stock-based awards, of which there were
no
new awards for the years ended
December 31, 2019
and
2018.
 
We calculate expected volatility for stock options by taking an average of historical volatility over the expected term. The computation of expected term was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards and vesting schedules. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury yield in effect at the time of grant. Forfeiture rates are calculated by dividing unvested shares forfeited by beginning shares outstanding. The pre-vesting forfeiture rate is calculated yearly and is determined using a historical
twelve
-quarter rolling average of the forfeiture rates.
 
The following tables summarize data for the stock options issued by us:
 
Year
e
nded December 31, 201
9
 
   
Number
of
share
s
   
Weighted
average
exercise
price
per share
   
Weighted
average
remaining contractual
term
   
Aggregate
intrinsic
value
 
Shares under option – January 1
   
1,576,087
    $
6.58
     
 
     
 
 
Options granted
   
282,500
     
8.27
     
 
     
 
 
Options exercised
   
(208,881
)    
4.45
     
 
     
 
 
Options forfeited or expired
   
(107,914
)    
10.93
     
 
     
 
 
Shares under option – December 31
   
1,541,792
    $
6.88
     
3.21
    $
1,991
 
Vested and expected to vest - December 31
   
1,445,563
    $
6.79
     
3.04
    $
1,959
 
                                 
Options exercisable – December 31
   
1,083,581
    $
6.28
     
2.09
    $
1,872
 
 
 
 
 
Year
e
nded December 31, 201
8
 
   
Number
of shares
   
Weighted
average
exercise
price
per share
 
Shares under option – January 1
   
1,860,211
    $
5.96
 
Options granted
   
217,500
     
9.68
 
Options exercised
   
(422,793
)    
4.49
 
Options forfeited or expired
   
(78,831
)    
11.75
 
Shares under option – December 31
   
1,576,087
    $
6.58
 
                 
Options exercisable – December 31
   
1,064,127
    $
5.89
 
 
The following table represents additional information about stock options outstanding at
December 31, 2019:
 
         
Option outstanding
   
Options exercisable
 
Range of
exercise prices
   
Number of
outstanding
options
   
Weighted-
average
remaining
contractual
life
   
Weighted-
average
exercise
price
   
Number of
options
exercisable
   
Weighted-
average
exercise
price
 
$3.22
-
$3.99
     
244,377
     
1.70
    $
3.82
     
244,377
    $
3.82
 
$4.00
-
$5.99
     
336,331
     
3.81
     
4.95
     
269,601
     
4.79
 
$6.00 
-
$9.99
     
761,084
     
4.02
     
7.89
     
369,603
     
6.99
 
$10.00
     
200,000
     
1.00
     
10.00
     
200,000
     
10.00
 
                                               
$3.22
-
$10.00
     
1,541,792
     
3.21
    $
6.88
     
1,083,581
    $
6.28
 
 
The weighted average fair value of options granted during the years ended
December 31, 2019
and
2018
was
$3.77
and
$4.22,
respectively. The total intrinsic value of options (which is the amount by which the stock price exceeded the exercise price of the options on the date of exercise) exercised during the years ended
December 31, 2019
and
2018
was
$931
and
$1,722,
respectively.
 
Cash received from option exercises under our stock-based compensation plans for the years ended
December 31, 2019
and
2018
was
$930
and
$1,568,
respectively.
 
c.
Restricted Stock Awards
 
In
April 2019,
20,000
shares of restricted stock were awarded to certain of our employees at a weighted-average grant date fair value of
$11.12
per share. In
January 2018,
17,500
shares of restricted stock were awarded to certain of our employees at a weighted-average grant date fair value of
$7.16
per share. All outstanding restricted shares vest in equal annual installments over
three
years. Unrecognized compensation cost related to these restricted shares was
$145
at
December 31, 2019.
 
d.
Reserved Shares
 
There were
486,272
shares of common stock available for future issuance under equity compensation plans as of
December 31, 2019.